Overview

Pharmacokinetics and Safety of Ertapenem in the Postpartum Period

Status:
Terminated
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The investigators are doing this study to learn more about the dosing and safety of ertapenem in women with suspected serious infections less than 42 days from the delivery of their infant.
Phase:
Phase 1
Details
Lead Sponsor:
Daniel Benjamin
Treatments:
Ertapenem